

DRUG PRIOR AUTHORIZATION COMMITTEE

March 19, 2020

AGENDA

Via WebEx ONLY

To Join the WebEx, please click the link below.

[Join Webex Meeting](#)

Meeting number (access code): 807 477 455

Join from a video system or application

Dial 807477455@stateofmo.webex.com

You can also dial 173.243.2.68 and enter your meeting number.

Join by phone

Tap to call in from a mobile device (attendees only)

[1-650-479-3207](tel:1-650-479-3207) Call-in toll number (US/Canada)

[Global call-in numbers](#)

10:00 - 10:05	Welcome, Announcements and Introductions	Chairperson
10:05 - 10:15	Minutes Review	Discussion/Approval
10:15 - 10:25	Pharmacy Program/ Budget Update	Elizabeth Short
10:25 - 10:35	DUR Update	Josh Moore

Old Business

10:35 – 10:45	A. Implementation Schedule (Criteria for Previously Approved Clinical Edits, Step Therapies and PA's)	Josh Moore
---------------	--	------------

New Business

10:45 – 11:00	B. Proposed Actions - New Drug/Product Review (See website and Attached Summary) <ul style="list-style-type: none">i. Open Accessii. Clinical Edit/Step Therapyiii. PDL Productsiv. Prior Authorization	Josh Moore
---------------	---	------------

11:00 – 11:45 **C. Clinical Edits**

Discussion, Public Hearing and Decision will be held for each edit.

- I. Acne or Rosacea – Select Topical Agents**
- II. Clobazam Agents**
- III. DMD**
- IV. Epidiolex**
- V. Galafold**
- VI. Givlaari**

- VII. **Megestrol Acetate**
- VIII. **Nocturnal Polyuria**
- IX. **Reblozyl**
- X. **Sickle Cell Disease**
- XI. **Spravato**
- XII. **Systemic Antifungals**

11:45 – 1:00

D. Preferred Drug List (PDL)

Discussion, Public Hearing and Decision will be held for each edit.

- I. **Actinic Keratosis Agents - Topical**
 - II. **Androgenic Agents**
 - III. **Antibiotics – Inhaled Agents**
 - IV. **Antifungal Agents – Oral**
 - V. **Antifungal Agents – Topical**
 - VI. **Antihistamines – Intranasal**
 - VII. **Antihistamines – Ophthalmic**
 - VIII. **Antihistamines/Decongestant Combinations – Low Sedating (2nd Generation)**
 - IX. **Antiparasitic Agents – Topical**
 - X. **Antiviral Agents – Herpes Oral**
 - XI. **Antiviral Agents – Topical**
 - XII. **Atopic Dermatitis Agents – Immunomodulators**
 - XIII. **Benzoyl Peroxide/Antibiotic Combinations**
 - XIV. **Beta-Adrenergic Agents – Long Acting**
 - XV. **Beta-Adrenergic Agents – Nebulized**
 - XVI. **Beta-Adrenergic Agents – Short Acting**
 - XVII. **COPD Agents**
 - XVIII. **Corticosteroids – Inhaled**
 - XIX. **Corticosteroids – Ophthalmic “Soft” Steroids**
 - XX. **Corticosteroids – Topical**
 - XXI. **Corticosteroids and Rhinitis Agents – Intranasal**
 - XXII. **Cough and Cold Preparations**
 - XXIII. **Epinephrine Self-Injectable Agents**
 - XXIV. **Fluoroquinolones – Ophthalmic**
 - XXV. **Fluoroquinolones – Otic**
 - XXVI. **Glaucoma Agents**

- XXVII. Leukotriene Receptor Modifiers
- XXVIII. Mast Cell Stabilizers – Ophthalmic
- XXIX. NSAIDs – Ophthalmic
- XXX. Pancreatic Enzyme Agents
- XXXI. Psoriasis Agents – Oral
- XXXII. Psoriasis Agents – Topical
- XXXIII. Retinoids – Topical
- XXXIV. Ulcerative Colitis Agents – Oral
- XXXV. Ulcerative Colitis Agents - Rectal

1:15-1:30
1:30-1:50

**Program Utilization Information - Conduent Update
Other Business**

Olivia Rush

- *“Top 25” Drugs by Cost/Claims*
- *Clinical Edit Summary Report*
- *Call Center Statistics*

Informal comments will be accepted from members of the audience at various points in the agenda. Times noted are approximate, Agenda may move more quickly.

NEXT MEETING: June 18, 2020

Department of Natural Resources
1101 Riverside Dr., Lacharette/Nightingale Rooms
Jefferson City, MO